TSE:ARZ Aralez Pharmaceuticals (ARZ) Stock Price, News & Analysis C$0.43 +0.04 (+10.26%) (As of 08/9/2018) Add Compare Share Share Today's RangeC$0.40▼C$0.5150-Day RangeC$0.43▼C$0.4352-Week RangeC$0.29▼C$3.72Volume274,400 shsAverage Volume79,103 shsMarket CapitalizationC$28.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aralez Pharmaceuticals alerts: Email Address Ad DTIEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during This 8-Day Profit Window? And when I say almost always… I really mean it. For over a year now, traders have had the chance to cash in during this time with an 83% success rate using these New Bitcoin Options. Now of course I can’t promise future returns or against losses…It’s coming up quick. About Aralez Pharmaceuticals Stock (TSE:ARZ)Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Read More ARZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARZ Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ARZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aralez Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorBasic Materials Industry Gold Sub-IndustryAircraft Current SymbolTSE:ARZ CUSIPN/A CIKN/A Webaralez.com Phone+1-905-8761118FaxN/AEmployees4,500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares67,194,000Free FloatN/AMarket CapC$28.89 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Adrian Adams (Age 67)CEO & Director Mr. Andrew I. Koven (Age 60)Pres & Chief Bus. Officer Mr. Michael Kaseta (Age 42)Chief Financial Officer Dr. James Patrick Tursi (Age 53)Chief Medical Officer Mr. John E. Barnhardt CPA (Age 68)Principal Accounting Officer and VP of Fin. & Admin. Key CompetitorsClean Air MetalsCVE:AIRSpirit AeroSystemsCNSX:SPRBombardierTSE:BBD.ALaurion Mineral ExplorationCVE:LMEQMX GoldCVE:QMXView All Competitors ARZ Stock Analysis - Frequently Asked Questions How have ARZ shares performed this year? Aralez Pharmaceuticals' stock was trading at C$0.43 at the beginning of 2024. Since then, ARZ stock has increased by 0.0% and is now trading at C$0.43. View the best growth stocks for 2024 here. How do I buy shares of Aralez Pharmaceuticals? Shares of ARZ stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Aralez Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aralez Pharmaceuticals investors own include Aralez Pharmaceuticals (ARLZ), Westport Fuel Systems (WPRT), Advantage Oil & Gas (AAV), Athabasca Oil (ATH), Yamana Gold (AUY), AVEO Pharmaceuticals (AVEO) and Anavex Life Sciences (AVXL). This page (TSE:ARZ) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aralez Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aralez Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.